Emergent BioSolutions stock
EBSNYSEEmergent BioSolutions Inc., HealthcareISIN US29089Q1058
24Score 24 out of 100, Weak
Price and trend
34 / 100
Price history
−46% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 24% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 58% below its 52-week high. Largest decline in 20 years: 99% (August 2020 to February 2024).
Chart figures for advanced users
- SMA 50$6.51
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.45
- The lowest closing price of the last twelve months.
- Resistance$13.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Emergent BioSolutions Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $302.84M, is number 78 of 78 companies in its industry on MEQIRI.
- MEQIRI Score 24 out of 100 (Weak): rank 714 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Earnings per share fallingDown 29.9% a year since 2020.Growth 5
- Revenue shrinkingRevenue down 14% a year since 2020.Growth 5
- Loss-makingLoss of $260.7M over the last 12 months.Fundamentals 37
The score is held back by momentum and growth.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 17.7% on the twelve months before. Revenue has grown solidly since 2006, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 47%, operating 15%, net 7%. Last 12 months: net −40%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 2 Nov 2026EPS reported −$0.36 (expected −$0.39)above expectations
Analyst estimates
- Earnings per share
- $0.29−19.5%
- Revenue
- $646.79M−1.6%
- Earnings per share
- $1.050.0%
- Revenue
- $703.33M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −29.9%2026 revenue guidance lowered to $645 million to $675 million from $720 million to $760 million, due to increased competition in NARCAN; the profitability outlook was also revised.
“We are revising full-year 2026 total revenue guidance to a range of $645 million to $675 million, compared with our prior range of $720 million to $760 million The revision primarily reflects lower expected commercial revenue in the second half of the year, driven by increased competitive pressure in NARCAN, as well …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $170,992 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Emergent BioSolutions
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 24
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger companies by market value
- EvotecEVT.DE $624.43M32
- Alpha TeknovaTKNO $541M43
- EvolusEOLS $491.12M45
- KamadaKMDA $468.95M66
- Aquestive TherapeuticsAQST $449.96M29
- BoironBOI.PA $371.89M56
- PharmaSGP HoldingPSG.DE $371.49M80
- Aurora CannabisACB $332.01M44
ETFs that hold Emergent BioSolutions
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.02% | 0.39% | €1.47B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 27 Feb 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.